Table 2.
Baseline characteristics of the subjects in ADNI cohorts 1, GO/2, and 1/GO/2.
| Variable | ADNI cohort 1 (N = 741) |
ADNI cohort GO/2 (N = 792) |
ADNI cohort 1/GO/2 (N = 1,546) |
|---|---|---|---|
| Sex | |||
| Female, No. (%) | 308 (41.57) | 368 (46.46) | 676 (43.73) |
| Male, No. (%) | 433 (58.43) | 424 (53.54) | 870 (56.27) |
| Age (in years), median (IQR) | 75.50 (71.20 ~ 80.00) | 72.60 (67.57 ~ 77.70) | 74.00 (69.33 ~ 78.97) |
| Education level (in years), median (IQR) | 16 (13 ~ 18) | 16 (14 ~ 18) | 16 (14 ~ 18) |
| APOE4 allelic dosage | |||
| 0, No. (%) | 373 (50.34) | 439 (55.43) | 817 (52.85) |
| 1, No. (%) | 290 (39.14) | 283 (35.73) | 579 (37.45) |
| 2, No. (%) | 78 (10.53) | 70 (8.84) | 150 (9.70) |
| Race | |||
| White, No. (%) | 671 (90.55) | 701 (88.51) | 1,384 (89.52) |
| African American, No. (%) | 37 (4.99) | 32 (4.04) | 69 (4.46) |
| Hispanic, No. (%) | 17 (2.29) | 34 (4.29) | 51 (3.30) |
| Others, No. (%) | 16 (2.16) | 25 (3.16) | 42 (2.72) |
| ADAS13 (in scores), median (IQR) | 18.00 (11.00 ~ 24.33) | 13.00 (8.00 ~ 20.00) | 15.00 (9.67 ~ 23.00) |
| CDRSB (in scores), median (IQR) | 1.5 (0 ~ 3.0) | 1.0 (0 ~ 2.0) | 1.0 (0 ~ 2.5) |
| RAVLT.learning (in scores), median (IQR) | 3 (2 ~ 6) | 4 (3 ~ 7) | 4 (2 ~ 6) |
| MMSE (in scores), median (IQR) | 27 (25 ~ 29) | 29 (26 ~ 30) | 28 (26 ~ 29) |
| FAQ (in scores), median (IQR) | 2.00 (0 ~ 8.00) | 1.00 (0 ~ 5.00) | 1.00 (0 ~ 6.00) |
| CSF ABETA (in pg./mL), median (IQR) | 694.15 (535.88 ~ 1229.25) | 928.75 (664.42 ~ 1532.50) | 858.70 (596.60 ~ 1406.00) |
| CSF TAU (in pg./mL), median (IQR) | 281.45 (209.85 ~ 368.45) | 246.75 (186.88 ~ 329.82) | 257.80 (193.50 ~ 351.80) |
| CSF PTAU (in pg./mL), median (IQR) | 27.18 (18.65 ~ 37.13) | 22.64 (16.74 ~ 32.22) | 24.08 (17.31 ~ 34.05) |
| FDG PET (in SUVR), median (IQR) | 1.24 (1.18 ~ 1.29) | 1.27 (1.22 ~ 1.32) | 1.26 (1.21 ~ 1.31) |
| Amyloid PET/AV45a (in SUVR), median (IQR) | – | 1.13 (1.02 ~ 1.40) | 1.13 (1.02 ~ 1.40) |
| FS WholeBrain (in mm3), mean ± SDb | 989673.62 ± 106621.05 | 1048929.29 ± 105742.11 | 1020009.00 ± 110047.70 |
| FS Hippocampus (in mm3), mean ± SDb | 6472.01 ± 1169.68 | 7036.37 ± 1127.23 | 6778.00 ± 1181.27 |
| FS Entorhinal (in mm3), mean ± SDb | 3332.98 ± 809.55 | 3632.71 ± 729.62 | 3491.00 ± 782.89 |
| FS Ventricles (in mm3), median (IQR) | 38509.00 (26164.75 ~ 55523.50) | 32916.00 (21764.00 ~ 48505.00) | 35549.00 (24229.00 ~ 51527.00) |
| FS MidTemp (in mm3), mean ± SDb | 18624.48 ± 3109.97 | 20157.52 ± 2834.14 | 19438.00 ± 3056.10 |
| FS Fusiform (in mm3), mean ± SDb | 16191.48 ± 2480.94 | 18226.60 ± 2630.74 | 17273.00 ± 2755.35 |
IQR, interquartile range; pg/mL, picograms per milliliter; SD, standard deviation; SUVR, standardized uptake volume ratio. aThe values of Amyloid PET/AV45 at baseline are missing in ADNI cohort 1. bThe descriptive characteristics of FS WholeBrain, FS Hippocampus, FS Entorhinal, FS MidTemp and FS Fusiform are presented as mean ± SD, since they asymptotically follow the normal distributions.